SciClone Message Board - Msg: 3331560

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SciClone

SCLN 11.15

0.0%

Oct 20 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tom Barnum who wrote (77)	2/3/1998 3:38:00 PM
From: JMarcus	Read Replies (1) of 93

4th Quarter results were disappointing. Does anyone know whether slow-payment from China continues to be a big problem? NEW YORK (Dow Jones)--Everen Securities Inc. downgraded its near- and long-term ratings on SciClone Pharmaceuticals Inc. (SCLN) to market perform from outperform. In a research note, the firm cited SciClone's fourth-quarter results, which failed to match Everen's expectations. As reported, SciClone posted a fourth-quarter loss of 25 cents a share, compared with a loss of 20 cents a year ago and Everen's projection of an 18-cent loss. Everen said SciClone is looking at financing alternatives but warned that it cannot be assured that it will find favorable options. Everen projects a 1998 loss of $1.49 a share, wider than its previous estimate of a loss of $1.13, and a 1999 loss of $1.67 a share, wider than its previous forecast of a $1.14 loss. - Gaston F. Ceron; 201-938-5174

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next